Tests Catalogs

MANNOSE-BINDING LECTIN

LAB3088

 

Collect

Serum separator tube, plain red, or green (lithium heparin).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min 0.2 mL)

Unacceptable Conditions

Specimens collected in EDTA or citrate. Contaminated or heat-inactivated specimens.

Storage/Transport Temperature

Frozen. Separate specimens must be submitted when multiple tests are ordered. Also acceptable: Refrigerated.

Stability (from collection to initiation)

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Performed

Tue

Methodology

Quantitative Enzyme-Linked Immunosorbent Assay

Reported

1-8 days

Synonyms

  • LAB3088
  • MBL
  • MANNBINDL

Additional Technical Information

Ordering Recommendations

Initial screening for suspected deficiency in the lectin complement pathway.

Reference Interval

Greater than 50 ng/mL

Interpretive Data

Mannose-binding protein is a component of the innate or natural immune system which binds to mannose residues on a variety of different microorganisms. When bound, this lectin will trigger the complement pathway resulting in opsonization. Mannose-binding protein is also an acute phase reactant produced by the liver. Patients who have abnormal levels of mannose-binding protein may have recurrent significant infections in the absence of abnormalities in the four major arms of the immune system. Abnormal mannose-binding protein concentrations have been found in patients with infectious disorders such as tuberculosis, hepatitis B, and in autoimmune disorders including recurrent spontaneous abortion and systemic lupus erythematosis.

CPT Codes

83520
Collection

LAB3088

 

Collect

Serum separator tube, plain red, or green (lithium heparin).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min 0.2 mL)

Unacceptable Conditions

Specimens collected in EDTA or citrate. Contaminated or heat-inactivated specimens.

Storage/Transport Temperature

Frozen. Separate specimens must be submitted when multiple tests are ordered. Also acceptable: Refrigerated.

Stability (from collection to initiation)

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Ordering

Performed

Tue

Methodology

Quantitative Enzyme-Linked Immunosorbent Assay

Reported

1-8 days

Synonyms

  • LAB3088
  • MBL
  • MANNBINDL

Additional Technical Information

Ordering Recommendations

Initial screening for suspected deficiency in the lectin complement pathway.
Result Interpretation

Reference Interval

Greater than 50 ng/mL

Interpretive Data

Mannose-binding protein is a component of the innate or natural immune system which binds to mannose residues on a variety of different microorganisms. When bound, this lectin will trigger the complement pathway resulting in opsonization. Mannose-binding protein is also an acute phase reactant produced by the liver. Patients who have abnormal levels of mannose-binding protein may have recurrent significant infections in the absence of abnormalities in the four major arms of the immune system. Abnormal mannose-binding protein concentrations have been found in patients with infectious disorders such as tuberculosis, hepatitis B, and in autoimmune disorders including recurrent spontaneous abortion and systemic lupus erythematosis.

Administrative

CPT Codes

83520

MANUAL DIFFERENTIAL

LAB1749

MAN DIFF

 

Collect

One 4 mL Purple top tube (EDTA).  Minimum volume 1.0 mL.

Pediatric Collection

At least 0.5 mL whole blood collected in a 1.0 mL microtainer, purple top, EDTA whole blood.

Unacceptable Conditions

Specimen not properly identified; incorrect container; clotted sample; frozen sample.

Storage/Transport Temperature

Internal: Deliver to lab immediately.
Offsite: Refrigerate if transport time is outside of ambient temperature stability guidelines.

Stability (from collection to initiation)

Ambient: 8 hours; Refrigerated: 36 hours.

Remarks

CBC must be ordered in addition to this test.

Performed by

PCL Clinical Laboratory - Core

Notes

Blood volume of 0.5 mL or less in a 4.0 mL purple top (EDTA whole blood) is unacceptable. Blood volume between 0.5 mL and 1.0 mL in a 4.0 mL purple top (EDTA whole blood) is a suboptimal specimen and results will be reported with this disclaimer: "Low volume sample, results may be unreliable."

Performed

Daily

Methodology

Microscopy

Reported

Routine requests are reported within 8 hours.

Synonyms

  • LAB1749
  • MANUAL DIFF
  • SEVAL
  • SLIDE EVALUATION

Reference Interval

NEUT ABS M/F 0 6D 5.0 21.0 10^9/L
M/F 6D 13D 1.5 10.0 10^9/L
M/F 13D 1 1.0 9.5 10^9/L
M/F 1 6 1.5 8.5 10^9/L
M/F 6 10 1.5 8.0 10^9/L
M/F 10 150 1.8 7.8 10^9/L
LYMPH ABS M/F 0 6D 2.0 11.5 10^9/L
M/F 6D 6M 2.0 17.0 10^9/L
M/F 6M 1 4.0 13.5 10^9/L
M/F 1 2 4.0 10.5 10^9/L
M/F 2 6 2.0 9.5 10^9/L
M/F 6 10 1.5 7.0 10^9/L
M/F 10 150 1.0 4.8 10^9/L
MONO ABS M/F 0 1W 0.7 2.0 10^9/L
M/F 1W 150 0.2 0.9 10^9/L
EO ABS M/F 0 6D 0.2 2.0 10^9/L
M/F 6D 1 0.1 1.1 10^9/L
M/F 1 10 0.0 0.7 10^9/L
M/F 10 150 0.0 0.4 10^9/L
BASO ABS M/F 0 6D 0.0 0.6 10^9/L
M/F 6D 150 0.0 0.2 10^9/L

Performed by

PCL Clinical Laboratory - Core

CPT Codes

85007

Collection

LAB1749

MAN DIFF

 

Collect

One 4 mL Purple top tube (EDTA).  Minimum volume 1.0 mL.

Pediatric Collection

At least 0.5 mL whole blood collected in a 1.0 mL microtainer, purple top, EDTA whole blood.

Unacceptable Conditions

Specimen not properly identified; incorrect container; clotted sample; frozen sample.

Storage/Transport Temperature

Internal: Deliver to lab immediately.
Offsite: Refrigerate if transport time is outside of ambient temperature stability guidelines.

Stability (from collection to initiation)

Ambient: 8 hours; Refrigerated: 36 hours.

Remarks

CBC must be ordered in addition to this test.

Performed by

PCL Clinical Laboratory - Core

Notes

Blood volume of 0.5 mL or less in a 4.0 mL purple top (EDTA whole blood) is unacceptable. Blood volume between 0.5 mL and 1.0 mL in a 4.0 mL purple top (EDTA whole blood) is a suboptimal specimen and results will be reported with this disclaimer: "Low volume sample, results may be unreliable."
Ordering

Performed

Daily

Methodology

Microscopy

Reported

Routine requests are reported within 8 hours.

Synonyms

  • LAB1749
  • MANUAL DIFF
  • SEVAL
  • SLIDE EVALUATION
Result Interpretation

Reference Interval

NEUT ABS M/F 0 6D 5.0 21.0 10^9/L
M/F 6D 13D 1.5 10.0 10^9/L
M/F 13D 1 1.0 9.5 10^9/L
M/F 1 6 1.5 8.5 10^9/L
M/F 6 10 1.5 8.0 10^9/L
M/F 10 150 1.8 7.8 10^9/L
LYMPH ABS M/F 0 6D 2.0 11.5 10^9/L
M/F 6D 6M 2.0 17.0 10^9/L
M/F 6M 1 4.0 13.5 10^9/L
M/F 1 2 4.0 10.5 10^9/L
M/F 2 6 2.0 9.5 10^9/L
M/F 6 10 1.5 7.0 10^9/L
M/F 10 150 1.0 4.8 10^9/L
MONO ABS M/F 0 1W 0.7 2.0 10^9/L
M/F 1W 150 0.2 0.9 10^9/L
EO ABS M/F 0 6D 0.2 2.0 10^9/L
M/F 6D 1 0.1 1.1 10^9/L
M/F 1 10 0.0 0.7 10^9/L
M/F 10 150 0.0 0.4 10^9/L
BASO ABS M/F 0 6D 0.0 0.6 10^9/L
M/F 6D 150 0.0 0.2 10^9/L

Performed by

PCL Clinical Laboratory - Core

Administrative

CPT Codes

85007

MATERNAL SCREEN -AFP ONLY

LAB692

 

Collect

One 5 mL gold or red top with gel (SST), serum (clot activator).

Specimen must be drawn between 14 weeks, 0 days and 24 weeks, 6 days gestation.

Pediatric Collection

Minimum volume: 1 mL serum

Unacceptable Conditions

Hemolyzed specimens; plasma; specimens exposed to repeated freeze/thaw cycles; specimen not properly identified; insufficient sample volume.

Storage/Transport Temperature

Internal: Deliver to lab immediately at ambient temperature.

External: Allow to clot for 30 minutes before centrifugation. Immediately centrifuge, then transport to lab at 2-8 degrees C.

Stability (from collection to initiation)

Before centrifugation: Ambient, 1 hour

After centrifugation: Ambient, 24 hours; Refrigerated, 1 week; Frozen, unacceptable.

Serum aliquot: Ambient, 24 hours; Refrigerated, 1 week; Frozen (-20 degrees C), 1 year.

Remarks

The following information is required and must accompany the sample for testinterpretation:

  • Maternal weight in pounds
  • Date of last menstrual period (LMP), or
  • Date of ultrasound and gestational age at ultrasound
  • Estimated date of delivery
  • Current pregnancy: Singleton, Twins, Multiple Fetuses
  • Mother's race
  • Mother's diabetic status; Insulin dependent?
  • Family history of Down syndrome or neural tube defect
  • If in vitro fertilization (IVF) pregnancy, donor's date of birth
  • Initial screening or repeat testing

Performed by

PCL Clinical Laboratory - Specials

Notes

This test is used to screen for fetal risk of Open Neural Tube Defect (i.e., spina bifida).

Performed

Monday and Thursday

Methodology

Quantitative Chemiluminescent Immunoassay

Reported

2-3 days

Synonyms

  • AFP (Maternal Serum Only)
  • LAB692
  • MS ONLY
  • MSAFP only

Reference Interval

By report: includes AFP.  Intervals are based upon weeks of gestation.

Performed by

PCL Clinical Laboratory - Specials

CPT Codes

82105
Collection

LAB692

 

Collect

One 5 mL gold or red top with gel (SST), serum (clot activator).

Specimen must be drawn between 14 weeks, 0 days and 24 weeks, 6 days gestation.

Pediatric Collection

Minimum volume: 1 mL serum

Unacceptable Conditions

Hemolyzed specimens; plasma; specimens exposed to repeated freeze/thaw cycles; specimen not properly identified; insufficient sample volume.

Storage/Transport Temperature

Internal: Deliver to lab immediately at ambient temperature.

External: Allow to clot for 30 minutes before centrifugation. Immediately centrifuge, then transport to lab at 2-8 degrees C.

Stability (from collection to initiation)

Before centrifugation: Ambient, 1 hour

After centrifugation: Ambient, 24 hours; Refrigerated, 1 week; Frozen, unacceptable.

Serum aliquot: Ambient, 24 hours; Refrigerated, 1 week; Frozen (-20 degrees C), 1 year.

Remarks

The following information is required and must accompany the sample for testinterpretation:

  • Maternal weight in pounds
  • Date of last menstrual period (LMP), or
  • Date of ultrasound and gestational age at ultrasound
  • Estimated date of delivery
  • Current pregnancy: Singleton, Twins, Multiple Fetuses
  • Mother's race
  • Mother's diabetic status; Insulin dependent?
  • Family history of Down syndrome or neural tube defect
  • If in vitro fertilization (IVF) pregnancy, donor's date of birth
  • Initial screening or repeat testing

Performed by

PCL Clinical Laboratory - Specials

Notes

This test is used to screen for fetal risk of Open Neural Tube Defect (i.e., spina bifida).
Ordering

Performed

Monday and Thursday

Methodology

Quantitative Chemiluminescent Immunoassay

Reported

2-3 days

Synonyms

  • AFP (Maternal Serum Only)
  • LAB692
  • MS ONLY
  • MSAFP only
Result Interpretation

Reference Interval

By report: includes AFP.  Intervals are based upon weeks of gestation.

Performed by

PCL Clinical Laboratory - Specials
Administrative

CPT Codes

82105

MATERNAL SERUM - QUADSCREEN

LAB560

 

Collect

One 5 mL gold or red top with gel (SST), serum (clot activator).

Specimen must be drawn between 14 weeks, 0 days and 24 weeks, 6 days gestation.

Pediatric Collection

Minimum volume: 1 mL serum

Unacceptable Conditions

Hemolyzed specimens; heparin, EDTA or citrate plasma; specimens exposed to repeated freeze/thaw cycles; specimen not properly identified; insufficient sample volume.

Storage/Transport Temperature

Internal:Deliver to lab immediately at ambient temperature.

External: Allow to clot for 30 minutes before centrifugation. Immediately centrifuge, then transport to lab at 2-8 degrees C.

Stability (from collection to initiation)

Before centrifugation: Ambient, 1 hour

After centrifugation: Ambient, 24 hours; Refrigerated, 1 week; Frozen, unacceptable.

Serum aliquot: Ambient, 24 hours; Refrigerated, 1 week; Frozen (-20 degrees C), 1 year.

Remarks

The following information is required and must accompany the sample for testinterpretation:

  • Maternal weight in pounds
  • Date of last menstrual period (LMP), or
  • Date of ultrasound and gestational age at ultrasound
  • Estimated date of delivery
  • Current pregnancy: Singleton, Twins, Multiple Fetuses
  • Mother's race
  • Mother's diabetic status; Insulin dependent?
  • Family history of Down syndrome or neural tube defect
  • If in vitro fertilization (IVF) pregnancy, donor's date of birth
  • Initial screening or repeat testing

 

Performed by

PCL Clinical Laboratory - Specials

Notes

This test is used to screen for fetal risk of Down syndrome (trisomy 21), trisomy 18, and Open Neural Tube Defect (ONTD, spina bifida).

Performed

Monday and Thursday

Methodology

Chemiluminescent Immunoassay

Reported

Same day

Synonyms

  • -171
  • LAB560

Reference Interval

By report: includes AFP, hCG, Estriol, and Inhibin A. Intervals are based upon weeks of gestation.

Performed by

PCL Clinical Laboratory - Specials

CPT Codes

81511

Collection

LAB560

 

Collect

One 5 mL gold or red top with gel (SST), serum (clot activator).

Specimen must be drawn between 14 weeks, 0 days and 24 weeks, 6 days gestation.

Pediatric Collection

Minimum volume: 1 mL serum

Unacceptable Conditions

Hemolyzed specimens; heparin, EDTA or citrate plasma; specimens exposed to repeated freeze/thaw cycles; specimen not properly identified; insufficient sample volume.

Storage/Transport Temperature

Internal:Deliver to lab immediately at ambient temperature.

External: Allow to clot for 30 minutes before centrifugation. Immediately centrifuge, then transport to lab at 2-8 degrees C.

Stability (from collection to initiation)

Before centrifugation: Ambient, 1 hour

After centrifugation: Ambient, 24 hours; Refrigerated, 1 week; Frozen, unacceptable.

Serum aliquot: Ambient, 24 hours; Refrigerated, 1 week; Frozen (-20 degrees C), 1 year.

Remarks

The following information is required and must accompany the sample for testinterpretation:

  • Maternal weight in pounds
  • Date of last menstrual period (LMP), or
  • Date of ultrasound and gestational age at ultrasound
  • Estimated date of delivery
  • Current pregnancy: Singleton, Twins, Multiple Fetuses
  • Mother's race
  • Mother's diabetic status; Insulin dependent?
  • Family history of Down syndrome or neural tube defect
  • If in vitro fertilization (IVF) pregnancy, donor's date of birth
  • Initial screening or repeat testing

 

Performed by

PCL Clinical Laboratory - Specials

Notes

This test is used to screen for fetal risk of Down syndrome (trisomy 21), trisomy 18, and Open Neural Tube Defect (ONTD, spina bifida).

Ordering

Performed

Monday and Thursday

Methodology

Chemiluminescent Immunoassay

Reported

Same day

Synonyms

  • -171
  • LAB560
Result Interpretation

Reference Interval

By report: includes AFP, hCG, Estriol, and Inhibin A. Intervals are based upon weeks of gestation.

Performed by

PCL Clinical Laboratory - Specials

Administrative

CPT Codes

81511

MECONIUM DRUG SCREEN - 9 DRUGS

LAB479

MEC 9

Collect

Meconium. All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears.

Storage/Transport Temperature

All meconium available (4 g is preferred) at 20-25°C. (Min: 2 g or 3/4 inch cube on each side)

Stability (from collection to initiation)

Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year

Performed by

PCL Clinical Laboratory

Notes

If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added. Additional charges apply.

Unless ARUP is otherwise notified, reflex confirmation testing will be performed in the following order of priority:

Amphetamines (0.125 g sample required)
Cocaine (0.5 g sample required)
Opiates (0.125 g required)
Buprenorphine (0.125 g required)
Marijuana (0.125 g required)
Benzodiazepines (0.5 g sample required)
Methadone (0.125 g sample required)
Phencyclidine - PCP (0.5 g sample required)
Barbiturates (0.5 g sample required)

Performed

Sun-Sat

Methodology

Qualitative Enzyme-Linked Immunosorbent Assay/Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Reported

1-4 days

Synonyms

  • MEC 9
  • LAB479
  • Pain Management
  • DRUGS OF ABUSE PANEL MECONIUM SCREEN W/REFLEX TO CONF

Additional Technical Information

Ordering Recommendations

Preferred meconium test to detect and document maternal drug use during pregnancy approximately the last trimester of a full-term birth. Targeted single-drug class testing is appropriate if only a particular drug class or classes are of clinical interest, or when quantity of meconium available for testing is very small (eg <1g).

Reference Interval

Drugs Covered and Cutoff Concentrations
Drug
Screen
Confirmation
Amphetamines30 ng/g20 ng/g
Barbiturates75 ng/g50 ng/g
Benzodiazepines75 ng/g20 ng/g
Buprenorphine40 ng/g20 ng/g
Cocaine30 ng/g20 ng/g
Marijuana30 ng/g5 ng/g
Methadone40 ng/g10 ng/g
Opiates30 ng/g20 ng/g
Phencyclidine15 ng/g10 ng/g

Interpretive Data

Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by the mother. Although not likely, drugs administered during labor and delivery may be detected in meconium. Interpretive questions should be directed to the laboratory.

The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive.

For medical purposes only; not valid for forensic use.

Performed by

PCL Clinical Laboratory

CPT Codes

80307; if positive, add appropriate CPT code(s): 80324; 80359; 80345; 80346; 80349; 80353; 80358; 80361; 80365; 80348; 83992 (Alt code: if positive, add appropriate CPT code(s): G0480)
Collection

LAB479

MEC 9

Collect

Meconium. All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears.

Storage/Transport Temperature

All meconium available (4 g is preferred) at 20-25°C. (Min: 2 g or 3/4 inch cube on each side)

Stability (from collection to initiation)

Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year

Performed by

PCL Clinical Laboratory

Notes

If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added. Additional charges apply.

Unless ARUP is otherwise notified, reflex confirmation testing will be performed in the following order of priority:

Amphetamines (0.125 g sample required)
Cocaine (0.5 g sample required)
Opiates (0.125 g required)
Buprenorphine (0.125 g required)
Marijuana (0.125 g required)
Benzodiazepines (0.5 g sample required)
Methadone (0.125 g sample required)
Phencyclidine - PCP (0.5 g sample required)
Barbiturates (0.5 g sample required)
Ordering

Performed

Sun-Sat

Methodology

Qualitative Enzyme-Linked Immunosorbent Assay/Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Reported

1-4 days

Synonyms

  • MEC 9
  • LAB479
  • Pain Management
  • DRUGS OF ABUSE PANEL MECONIUM SCREEN W/REFLEX TO CONF

Additional Technical Information

Ordering Recommendations

Preferred meconium test to detect and document maternal drug use during pregnancy approximately the last trimester of a full-term birth. Targeted single-drug class testing is appropriate if only a particular drug class or classes are of clinical interest, or when quantity of meconium available for testing is very small (eg <1g).
Result Interpretation

Reference Interval

Drugs Covered and Cutoff Concentrations
Drug
Screen
Confirmation
Amphetamines30 ng/g20 ng/g
Barbiturates75 ng/g50 ng/g
Benzodiazepines75 ng/g20 ng/g
Buprenorphine40 ng/g20 ng/g
Cocaine30 ng/g20 ng/g
Marijuana30 ng/g5 ng/g
Methadone40 ng/g10 ng/g
Opiates30 ng/g20 ng/g
Phencyclidine15 ng/g10 ng/g

Interpretive Data

Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by the mother. Although not likely, drugs administered during labor and delivery may be detected in meconium. Interpretive questions should be directed to the laboratory.

The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive.

For medical purposes only; not valid for forensic use.

Performed by

PCL Clinical Laboratory

Administrative

CPT Codes

80307; if positive, add appropriate CPT code(s): 80324; 80359; 80345; 80346; 80349; 80353; 80358; 80361; 80365; 80348; 83992 (Alt code: if positive, add appropriate CPT code(s): G0480)

MEGALOBLASTIC ANEMIA PROFILE

LAB3485

 

Collect

One 7 mL gold with gel. or one 7 mL green (heparin) [Min vol: 3 mL]

Unacceptable Conditions

Plasma from blue top (Sodium citrate) or yellow top tubes; Specimen received not separated from cells; Citrate interferes with assay; homocysteine results increase by approximately 35% and 75% for specimens not centrifuged and/or not separated from the cl

Storage/Transport Temperature

Internal: Deliver to lab immediatley
Offsite: 1 mL Separate serum/plasma from cells within 1 hour of collection and transfer to plastic transport tube, refrigerate and deliver to the lab.

Stability (from collection to initiation)

Ambient: Unstable; Refrigerated: 1 week; Frozen

Remarks

Group contains the following tests:
cystathionine, homocysteine, 2-methylcitric acid,
methylmalonic acid.

Performed by

LABCorp Laboratory Services

Notes

82136, 83918

Performed

Mon - Thu

Methodology

Gas chromatography/mass spectrometry (GC/MS).

Reported

7 - 10 days

Synonyms

  • B12 DEFICIENCY PROFILE
  • VITAMIN B12 DEFICIENCY PROFILE
  • LAB3485
  • MEGALOANEM
  • MEGAL

Reference Interval

By report

Performed by

LABCorp Laboratory Services

Collection

LAB3485

 

Collect

One 7 mL gold with gel. or one 7 mL green (heparin) [Min vol: 3 mL]

Unacceptable Conditions

Plasma from blue top (Sodium citrate) or yellow top tubes; Specimen received not separated from cells; Citrate interferes with assay; homocysteine results increase by approximately 35% and 75% for specimens not centrifuged and/or not separated from the cl

Storage/Transport Temperature

Internal: Deliver to lab immediatley
Offsite: 1 mL Separate serum/plasma from cells within 1 hour of collection and transfer to plastic transport tube, refrigerate and deliver to the lab.

Stability (from collection to initiation)

Ambient: Unstable; Refrigerated: 1 week; Frozen

Remarks

Group contains the following tests:
cystathionine, homocysteine, 2-methylcitric acid,
methylmalonic acid.

Performed by

LABCorp Laboratory Services

Notes

82136, 83918

Ordering

Performed

Mon - Thu

Methodology

Gas chromatography/mass spectrometry (GC/MS).

Reported

7 - 10 days

Synonyms

  • B12 DEFICIENCY PROFILE
  • VITAMIN B12 DEFICIENCY PROFILE
  • LAB3485
  • MEGALOANEM
  • MEGAL
Result Interpretation

Reference Interval

By report

Performed by

LABCorp Laboratory Services

Administrative

MEMORY B CELLS - CD27/CD19/IGD

LAB3126

 

Collect

Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).

Specimen Preparation

Transport 4 mL whole blood. (Min: 0.5 mL)

Unacceptable Conditions

Specimens older than 48 hours. Clotted or hemolyzed specimens.

Storage/Transport Temperature

Room temperature. Also acceptable: Refrigerated.

Stability (from collection to initiation)

Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable

Remarks

Specimens must be analyzed within 48 hours of collection.

Notes

Reference intervals for IgM-only memory B-cells have currently been established only for populations aged 16-years and older. For all other B-cell subsets, reference intervals for populations younger than 16-years are adopted from literature. Piatosa B, Wolska-Kusnierz B, Pac M, Siewiera K, Galkowska E, Bernatowska E. B cell subsets in healthy children: Reference values for evaluation of B cell maturation process in peripheral blood. Cytometry Part B 2010; 78B: 372381.

Performed

Sun-Sat

Methodology

Flow Cytometry

Reported

1-3 days

Synonyms

  • LAB3126
  • MEMBCELL

Additional Technical Information

Ordering Recommendations

Assess B-cell subsets of immunodeficiencies. Supports the diagnosis of common variable immune deficiency (CVID) and may help predict the clinical phenotype. Assess B-cell reconstitution after bone marrow or hematopoietic stem cell transplantation. Not recommended for rituximab monitoring; refer to B-Cell CD20 Expression (0092099).

Reference Interval

Effective May 16, 2016
Available SeparatelyComponentsReference Interval
2-5 months5-9 months9-15 months15-24 months2-5 years5-10 years10-16 years16 years and older
NoB-cells % CD1918-38 %16-34 %14-28 %16-34 %14-29 %10-24 %9-23 %5-26 %
NoB-cells Absolute CD19700-2400 cells/µL700-2800 cells/µL400-2900 cells/µL600-1900 cells/µL400-1700 cells/µL300-600 cells/µL200-600 cells/µL58-558 cells/µL
NoNaive B-cell % CD19+/CD27-/IgD+82-95 %86-93 %77-95 %68-89 %54-88 %47-77 %51-83 %29-93 %
NoNaive B-cell Absolute CD19+/CD27-/IgD+620-2120 cells/µL600-2590 cells/µL360-2800 cells/µL490-1560 cells/µL280-1330 cells/µL130-460 cells/µL120-430 cells/µL22-423 cells/µL
NoClass-switched Mem%CD19+/CD27+/IgD-/IgM-0-9 %2-7 %1-12 %4-14 %5-21 %11-30 %9-26 %3-23 %
NoClass-switched Abs CD19+/CD27+/IgD-/IgM-10-170 cells/µL20-140 cells/µL10-100 cells/µL30-180 cells/µL20-220 cells/µL40-140 cells/µL30-110 cells/µL4-62 cells/µL
NoNon-Switched Mem %CD19+/CD27+/IgD+/IgM+3-9 %3-7 %3-11 %4-14 %3-20 %5-20 %5-18 %2-25 %
NoNon-switched Abs CD19+/CD27+/IgD+/IgM+20-200 cells/µL30-120 cells/µL20-140 cells/µL30-170 cells/µL20-180 cells/µL20-100 cells/µL20-70 cells/µL4-66 cells/µL
NoTotal Memory B-cell % CD19+/CD27+3-12 %5-12 %4-21 %10-27 %8-37 %19-47 %13-48 %7-48 %
NoTotal Memory B-cell Absolute CD19+/CD27+40-230 cells/µL50-270 cells/µL40-190 cells/µL50-330 cells/µL50-390 cells/µL60-230 cells/µL50-200 cells/µL13-148 cells/µL
NoIgM Only Memory Pct CD19+CD27+1gD-IgM+0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %
NoIgM Only Memory Abs CD19+CD27+IgD-IgM+0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL

Interpretive Data

This panel is indicated for patients with suspected immune deficiencies, especially Common Variable Immune Deficiency (CVID), and to assess reconstitution of B-cell subsets after bone marrow or stem cell transplant. Subsets measured: B-cells (CD19+), total memory B-cells (CD19+ CD27+), class switched memory B-cells (CD19+ CD27+ IgD- IgM-), non-switched/marginal zone memory B-cells (CD19+ CD27+ IgD+ IgM+), IgM only memory B-cells (CD19+ CD27+ IgD-IgM+), and naive B-cells (CD19+ CD27-IgD+).

CPT Codes

86355; 86356 x3
Collection

LAB3126

 

Collect

Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).

Specimen Preparation

Transport 4 mL whole blood. (Min: 0.5 mL)

Unacceptable Conditions

Specimens older than 48 hours. Clotted or hemolyzed specimens.

Storage/Transport Temperature

Room temperature. Also acceptable: Refrigerated.

Stability (from collection to initiation)

Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable

Remarks

Specimens must be analyzed within 48 hours of collection.

Notes

Reference intervals for IgM-only memory B-cells have currently been established only for populations aged 16-years and older. For all other B-cell subsets, reference intervals for populations younger than 16-years are adopted from literature. Piatosa B, Wolska-Kusnierz B, Pac M, Siewiera K, Galkowska E, Bernatowska E. B cell subsets in healthy children: Reference values for evaluation of B cell maturation process in peripheral blood. Cytometry Part B 2010; 78B: 372381.
Ordering

Performed

Sun-Sat

Methodology

Flow Cytometry

Reported

1-3 days

Synonyms

  • LAB3126
  • MEMBCELL

Additional Technical Information

Ordering Recommendations

Assess B-cell subsets of immunodeficiencies. Supports the diagnosis of common variable immune deficiency (CVID) and may help predict the clinical phenotype. Assess B-cell reconstitution after bone marrow or hematopoietic stem cell transplantation. Not recommended for rituximab monitoring; refer to B-Cell CD20 Expression (0092099).
Result Interpretation

Reference Interval

Effective May 16, 2016
Available SeparatelyComponentsReference Interval
2-5 months5-9 months9-15 months15-24 months2-5 years5-10 years10-16 years16 years and older
NoB-cells % CD1918-38 %16-34 %14-28 %16-34 %14-29 %10-24 %9-23 %5-26 %
NoB-cells Absolute CD19700-2400 cells/µL700-2800 cells/µL400-2900 cells/µL600-1900 cells/µL400-1700 cells/µL300-600 cells/µL200-600 cells/µL58-558 cells/µL
NoNaive B-cell % CD19+/CD27-/IgD+82-95 %86-93 %77-95 %68-89 %54-88 %47-77 %51-83 %29-93 %
NoNaive B-cell Absolute CD19+/CD27-/IgD+620-2120 cells/µL600-2590 cells/µL360-2800 cells/µL490-1560 cells/µL280-1330 cells/µL130-460 cells/µL120-430 cells/µL22-423 cells/µL
NoClass-switched Mem%CD19+/CD27+/IgD-/IgM-0-9 %2-7 %1-12 %4-14 %5-21 %11-30 %9-26 %3-23 %
NoClass-switched Abs CD19+/CD27+/IgD-/IgM-10-170 cells/µL20-140 cells/µL10-100 cells/µL30-180 cells/µL20-220 cells/µL40-140 cells/µL30-110 cells/µL4-62 cells/µL
NoNon-Switched Mem %CD19+/CD27+/IgD+/IgM+3-9 %3-7 %3-11 %4-14 %3-20 %5-20 %5-18 %2-25 %
NoNon-switched Abs CD19+/CD27+/IgD+/IgM+20-200 cells/µL30-120 cells/µL20-140 cells/µL30-170 cells/µL20-180 cells/µL20-100 cells/µL20-70 cells/µL4-66 cells/µL
NoTotal Memory B-cell % CD19+/CD27+3-12 %5-12 %4-21 %10-27 %8-37 %19-47 %13-48 %7-48 %
NoTotal Memory B-cell Absolute CD19+/CD27+40-230 cells/µL50-270 cells/µL40-190 cells/µL50-330 cells/µL50-390 cells/µL60-230 cells/µL50-200 cells/µL13-148 cells/µL
NoIgM Only Memory Pct CD19+CD27+1gD-IgM+0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %0.3-6.0 %
NoIgM Only Memory Abs CD19+CD27+IgD-IgM+0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL0.6-16.4 cells/µL

Interpretive Data

This panel is indicated for patients with suspected immune deficiencies, especially Common Variable Immune Deficiency (CVID), and to assess reconstitution of B-cell subsets after bone marrow or stem cell transplant. Subsets measured: B-cells (CD19+), total memory B-cells (CD19+ CD27+), class switched memory B-cells (CD19+ CD27+ IgD- IgM-), non-switched/marginal zone memory B-cells (CD19+ CD27+ IgD+ IgM+), IgM only memory B-cells (CD19+ CD27+ IgD-IgM+), and naive B-cells (CD19+ CD27-IgD+).

Administrative

CPT Codes

86355; 86356 x3

MERCURY URINE

LAB408

 

Collect

24-hour or random urine collection. Specimen must be collected in a plastic container. ARUP studies indicate that refrigeration of urine alone, during and after collection, preserves specimens adequately, if tested within 14 days of collection.

Patient Preparation

Diet, medication, and nutritional supplements may introduce interfering substances. Patients should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician). High concentrations of iodine may interfere with elemental testing. Abstinence from iodine-containing medications or contrast agents for at least 1 month prior to collecting specimens for elemental testing is recommended.

Specimen Preparation

Transfer an 8 mL aliquot from a well-mixed collection to ARUP Trace Element-Free Transport Tubes (ARUP supply #43116). Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 1 mL)

Unacceptable Conditions

Urine collected within 48 hours after administration of a gadolinium (Gd) containing contrast media (may occur with MRI studies). Acid preserved urine. Specimens contaminated with blood or fecal material. Specimens transported in non-trace element free transport tube (with the exception of the original device).

Storage/Transport Temperature

Refrigerated. Also acceptable: Room temperature or frozen.

Stability (from collection to initiation)

Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 1 year

Remarks

Trace Elements requisition form may be required (ARUP form #32990-Barcode; #32991-No Barcode). Record total volume and collection time interval on transport tube and on test request form.

Performed

Sun-Sat

Methodology

Quantitative Inductively Coupled Plasma-Mass Spectrometry

Reported

1-4 days

Synonyms

  • Hg, Urine
  • LAB408
  • MERC
  • MERCURY U

Ordering Recommendations

May be useful in the assessment of acute or chronic elemental or inorganic mercury exposure and/or in monitoring chelation therapy. For the assessment of acute exposure, Mercury, Whole Blood (0099305) is preferred.

Reference Interval

Effective May 19, 2014
Components
Reference Interval
Mercury, Urine - per 24h0-15 µg/d
Mercury, Urine - per volume0-10 µg/L
Mercury, Urine - ratio to CRTLess than or equal to 35 µg/gCRT
Creatinine, 24-Hour Urine
Age
Male
Female
3-8 years140-700 mg/d140-700 mg/d
9-12 years300-1300 mg/d300-1300 mg/d
13-17 years500-2300 mg/d400-1600 mg/d
18-50 years1000-2500 mg/d700-1600 mg/d
51-80 years800-2100 mg/d500-1400 mg/d
81 years and older600-2000 mg/d400-1300 mg/d


Interpretive Data

Urinary mercury levels predominantly reflect acute or chronic elemental or inorganic mercury exposure. Urine concentrations in unexposed individuals are typically less than 10 µg/L. 24 hour urine concentrations of 30 to 100 µg/L may be associated with subclinical neuropsychiatric symptoms and tremor while concentrations greater than 100 µg/L can be associated with overt neuropsychiatric disturbances and tremors. Urine mercury levels may be useful in monitoring chelation therapy.

CPT Codes

83825
Collection

LAB408

 

Collect

24-hour or random urine collection. Specimen must be collected in a plastic container. ARUP studies indicate that refrigeration of urine alone, during and after collection, preserves specimens adequately, if tested within 14 days of collection.

Patient Preparation

Diet, medication, and nutritional supplements may introduce interfering substances. Patients should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician). High concentrations of iodine may interfere with elemental testing. Abstinence from iodine-containing medications or contrast agents for at least 1 month prior to collecting specimens for elemental testing is recommended.

Specimen Preparation

Transfer an 8 mL aliquot from a well-mixed collection to ARUP Trace Element-Free Transport Tubes (ARUP supply #43116). Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 1 mL)

Unacceptable Conditions

Urine collected within 48 hours after administration of a gadolinium (Gd) containing contrast media (may occur with MRI studies). Acid preserved urine. Specimens contaminated with blood or fecal material. Specimens transported in non-trace element free transport tube (with the exception of the original device).

Storage/Transport Temperature

Refrigerated. Also acceptable: Room temperature or frozen.

Stability (from collection to initiation)

Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 1 year

Remarks

Trace Elements requisition form may be required (ARUP form #32990-Barcode; #32991-No Barcode). Record total volume and collection time interval on transport tube and on test request form.
Ordering

Performed

Sun-Sat

Methodology

Quantitative Inductively Coupled Plasma-Mass Spectrometry

Reported

1-4 days

Synonyms

  • Hg, Urine
  • LAB408
  • MERC
  • MERCURY U

Ordering Recommendations

May be useful in the assessment of acute or chronic elemental or inorganic mercury exposure and/or in monitoring chelation therapy. For the assessment of acute exposure, Mercury, Whole Blood (0099305) is preferred.
Result Interpretation

Reference Interval

Effective May 19, 2014
Components
Reference Interval
Mercury, Urine - per 24h0-15 µg/d
Mercury, Urine - per volume0-10 µg/L
Mercury, Urine - ratio to CRTLess than or equal to 35 µg/gCRT
Creatinine, 24-Hour Urine
Age
Male
Female
3-8 years140-700 mg/d140-700 mg/d
9-12 years300-1300 mg/d300-1300 mg/d
13-17 years500-2300 mg/d400-1600 mg/d
18-50 years1000-2500 mg/d700-1600 mg/d
51-80 years800-2100 mg/d500-1400 mg/d
81 years and older600-2000 mg/d400-1300 mg/d


Interpretive Data

Urinary mercury levels predominantly reflect acute or chronic elemental or inorganic mercury exposure. Urine concentrations in unexposed individuals are typically less than 10 µg/L. 24 hour urine concentrations of 30 to 100 µg/L may be associated with subclinical neuropsychiatric symptoms and tremor while concentrations greater than 100 µg/L can be associated with overt neuropsychiatric disturbances and tremors. Urine mercury levels may be useful in monitoring chelation therapy.

Administrative

CPT Codes

83825

MERCURY WHOLE BLOOD

LAB831

 

Collect

Royal blue (K2EDTA or Na2EDTA).

Patient Preparation

Diet, medication, and nutritional supplements may introduce interfering substances. Patient should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician), and avoid shellfish and seafood for 48 to 72 hours.

Specimen Preparation

Transport 7 mL whole blood in the original collection tube. (Min: 1 mL)

Unacceptable Conditions

Heparin anticoagulant. Frozen specimens.

Storage/Transport Temperature

Room temperature. Also acceptable: Refrigerated.

Stability (from collection to initiation)

Mercury is volatile; concentration may reduce after seven or more days of storage.

Remarks

Trace Elements requisition form may be required (ARUP form #32990).

Notes

Elevated results from noncertified trace element-free collection tubes may be due to contamination.  Elevated concentrations of trace elements in blood should be confirmed with a second specimen collected in a tube designed for trace element determinations, such as a royal blue (Na2EDTA) tube.

Performed

Sun-Sat

Methodology

Quantitative Atomic Absorption/Quantitative Inductively Coupled Plasma-Mass Spectrometry

Reported

1-2 days

Synonyms

  • Hg, Blood
  • LAB831
  • MERC

Ordering Recommendations

Preferred test for the assessment of acute mercury exposure. For chronic exposure, Mercury, Urine (0025050) is preferred.

Reference Interval

0-10 µg/L

Interpretive Data

Blood mercury levels predominantly reflect recent exposure and are most useful in the diagnosis of acute poisoning as blood mercury concentrations rise sharply and fall quickly over several days after ingestion. Blood concentrations in unexposed individuals rarely exceed 20 µg/L. The provided reference interval relates to inorganic mercury concentrations. Dietary and non-occupational exposure to organic mercury forms may contribute to an elevated total mercury result. Clinical presentation after toxic exposure to organic mercury may include dysarthria, ataxia and constricted vision fields with mercury blood concentrations from 20 to 50 µg/L.

CPT Codes

83825
Collection

LAB831

 

Collect

Royal blue (K2EDTA or Na2EDTA).

Patient Preparation

Diet, medication, and nutritional supplements may introduce interfering substances. Patient should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician), and avoid shellfish and seafood for 48 to 72 hours.

Specimen Preparation

Transport 7 mL whole blood in the original collection tube. (Min: 1 mL)

Unacceptable Conditions

Heparin anticoagulant. Frozen specimens.

Storage/Transport Temperature

Room temperature. Also acceptable: Refrigerated.

Stability (from collection to initiation)

Mercury is volatile; concentration may reduce after seven or more days of storage.

Remarks

Trace Elements requisition form may be required (ARUP form #32990).

Notes

Elevated results from noncertified trace element-free collection tubes may be due to contamination.  Elevated concentrations of trace elements in blood should be confirmed with a second specimen collected in a tube designed for trace element determinations, such as a royal blue (Na2EDTA) tube.
Ordering

Performed

Sun-Sat

Methodology

Quantitative Atomic Absorption/Quantitative Inductively Coupled Plasma-Mass Spectrometry

Reported

1-2 days

Synonyms

  • Hg, Blood
  • LAB831
  • MERC

Ordering Recommendations

Preferred test for the assessment of acute mercury exposure. For chronic exposure, Mercury, Urine (0025050) is preferred.
Result Interpretation

Reference Interval

0-10 µg/L

Interpretive Data

Blood mercury levels predominantly reflect recent exposure and are most useful in the diagnosis of acute poisoning as blood mercury concentrations rise sharply and fall quickly over several days after ingestion. Blood concentrations in unexposed individuals rarely exceed 20 µg/L. The provided reference interval relates to inorganic mercury concentrations. Dietary and non-occupational exposure to organic mercury forms may contribute to an elevated total mercury result. Clinical presentation after toxic exposure to organic mercury may include dysarthria, ataxia and constricted vision fields with mercury blood concentrations from 20 to 50 µg/L.

Administrative

CPT Codes

83825

METANEPHRINES PLASMA [FREE]

LAB3130

 

Collect

Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).

Patient Preparation

Drugs and medications may affect results and should be discontinued for at least 72 hours prior to specimen collection, if possible. Collection of the specimen after the patient has rested for 15 minutes in a supine position is recommended.

Specimen Preparation

Centrifuge within 1 hour. Transfer 2 mL plasma to an ARUP Standard Transport Tube and freeze immediately. (Min: 1 mL) Avoid hemolysis.

Unacceptable Conditions

Plasma separator tubes. Body fluids other than EDTA or heparinized plasma. Non-frozen specimens.

Storage/Transport Temperature

Centrifuge in refrigerated centrifuge (at 4C) if possible.

If not, place tube in ice bath for 5-10 minutes prior to centrifugation then centrifuge and aliquot ASAP.

Stability (from collection to initiation)

After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month

Notes

Isoetharine, isoproterenol, 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA) are known to interfere in this test.

Many drugs/medications, including over-the-counter and herbal products, can interfere with test results. Testing for all potential interactions is not possible.  If the patient is taking a drug not listed as an interferent, its potential effect on test results is unknown. If test results are inconsistent with clinical evidence, drug interference should be considered. If appropriate, the patient should discontinue the potential interferent for 48-72 hours and a new sample collected for retesting.

Performed

Sun-Sat

Methodology

Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Reported

2-6 days

Synonyms

  • Normetanephrine, Plasma
  • Metanephrine, Plasma
  • Quantitative Metanephrines
  • LAB3130
  • META PF
  • METANEPHFR

Ordering Recommendations

First-line test in suspected pheochromocytoma.

Reference Interval

Normetanephrine: 0.0-0.89 nmol/L
Metanephrine: 0.0-0.49 nmol/L

Interpretive Data

This test is useful in the detection of pheochromocytoma, a rare neuroendocrine tumor. The majority of patients with pheochromocytoma have a plasma normetanephrine concentration in excess of 2.2 nmol/L and/or a metanephrine concentration in excess of 1.1 nmol/L. Increased concentrations of these analytes serve as confirmation for diagnosis. Patients with essential hypertension and plasma concentrations of normetanephrine below 0.9 nmol/L and a metanephrine concentration below 0.5 nmol/L, can be excluded from further testing. If clinical suspicion remains, repeat testing or testing for metanephrines in a 24-hr. urine specimen should be considered.

CPT Codes

83835
Collection

LAB3130

 

Collect

Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).

Patient Preparation

Drugs and medications may affect results and should be discontinued for at least 72 hours prior to specimen collection, if possible. Collection of the specimen after the patient has rested for 15 minutes in a supine position is recommended.

Specimen Preparation

Centrifuge within 1 hour. Transfer 2 mL plasma to an ARUP Standard Transport Tube and freeze immediately. (Min: 1 mL) Avoid hemolysis.

Unacceptable Conditions

Plasma separator tubes. Body fluids other than EDTA or heparinized plasma. Non-frozen specimens.

Storage/Transport Temperature

Centrifuge in refrigerated centrifuge (at 4C) if possible.

If not, place tube in ice bath for 5-10 minutes prior to centrifugation then centrifuge and aliquot ASAP.

Stability (from collection to initiation)

After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month

Notes

Isoetharine, isoproterenol, 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA) are known to interfere in this test.

Many drugs/medications, including over-the-counter and herbal products, can interfere with test results. Testing for all potential interactions is not possible.  If the patient is taking a drug not listed as an interferent, its potential effect on test results is unknown. If test results are inconsistent with clinical evidence, drug interference should be considered. If appropriate, the patient should discontinue the potential interferent for 48-72 hours and a new sample collected for retesting.
Ordering

Performed

Sun-Sat

Methodology

Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Reported

2-6 days

Synonyms

  • Normetanephrine, Plasma
  • Metanephrine, Plasma
  • Quantitative Metanephrines
  • LAB3130
  • META PF
  • METANEPHFR

Ordering Recommendations

First-line test in suspected pheochromocytoma.
Result Interpretation

Reference Interval

Normetanephrine: 0.0-0.89 nmol/L
Metanephrine: 0.0-0.49 nmol/L

Interpretive Data

This test is useful in the detection of pheochromocytoma, a rare neuroendocrine tumor. The majority of patients with pheochromocytoma have a plasma normetanephrine concentration in excess of 2.2 nmol/L and/or a metanephrine concentration in excess of 1.1 nmol/L. Increased concentrations of these analytes serve as confirmation for diagnosis. Patients with essential hypertension and plasma concentrations of normetanephrine below 0.9 nmol/L and a metanephrine concentration below 0.5 nmol/L, can be excluded from further testing. If clinical suspicion remains, repeat testing or testing for metanephrines in a 24-hr. urine specimen should be considered.

Administrative

CPT Codes

83835

More Articles...